US EditionPublished • loading... • Updated
Takeda’s dengue vaccine offers seven-year protection in pivotal trial
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Phase 3 study confirms that Qdenga vaccine maintains long-term efficacy and safety against four types of dengue virus
Takeda’s dengue vaccine offers seven-year protection in pivotal trial
Despite the muted success of Sanofi's Dengvaxia in the global market, GD analysts forecast a rosy outlook for Takeda's dengue jab, Qdenga.The post Takeda’s dengue vaccine offers seven-year protection in pivotal trial appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
